AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Fifty 1 Labs, Inc.
Video analysis: FITY
All videosNo video analysis for this stock yet. Request one from our team.
News: FITY
Fifty 1 Labs, Inc. Acquires MSK Signal Recovery Product Line to Accelerate Growth in the Peptide and Musculoskeletal Health Market
Acquisition expands Fifty 1 Labs' portfolio with a five-product musculoskeletal recovery platform focused on injury recovery, rehabilitation, connective tissue support, joint health, and peptide-focused research VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an emerging biotechnology and health innovation company focused on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness, today announced that it has acquired a musculoskeletal recovery product line from MSK Signal, a Canadian Biotech Company. The acquired product line includes five key product concepts designed to support Fifty 1 Labs' growth strategy in the peptide and musculoskeletal health markets.
Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform
Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.
Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth
Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation. The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform.
Similar companies
-
FinCanna Capital Corp.
FNNZF
·
Other OTC
Compare
-
Jianpu Technology Inc.
AIJTY
·
Other OTC
Compare
-
Atlantis Technology Group
ATNPQ
·
Other OTC
Compare
-
China Solar & Clean Energy Solutions, Inc.
CSOL
·
Other OTC
Compare
-
Towne Bancorp, Inc.
TWNE
·
Other OTC
Compare
-
BioEnergy Development Inc.
CNER
·
Other OTC
Compare